Zydus Lifesciences Receives USFDA Establishment Inspection Report for Injectable Facility
Zydus Lifesciences Ltd has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) concerning its injectable facility. The facility is located at Zydus Biotech Park in Ahmedabad, and the report carries a Voluntary Action Indicated (VAI) classification.The EIR marks an important milestone for the company's production capabilities in the sterile drug manufacturing sector. The USFDA conducted the GMP surveillance inspection of the facility between April 27 and May 5, 2026.
This designation signifies that Zydus Lifesciences has successfully undergone a major regulatory review process regarding its injectable production standards at the Ahmedabad site.
ZYDUSLIFE Stock Price Movement
Shares of Zydus Lifesciences Ltd. edged higher on Friday, closing at ₹1126.80 after gaining 0.89% in session. The equity saw strong trading activity, with 721,020 shares transacting during the day's historical period.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.